Small Molecules API Segment Expected to Generate Substantial Growth Opportunities in the Forecast Period

20 Aug 2019: An active pharmaceutical ingredient (API) is mainly employed in a finished pharmaceutical product (FPP) with an aim to transport specific pharmacological actions. In addition, it can have a direct result in the cure, diagnosis, treatment, prevention, or mitigation of numerous disorders and in some situations, in correcting, restoring, or changing human physiological functions.

Cardiology segment estimated to account for the largest share in 2018

The major application variants in the active pharmaceutical ingredient (API) market include oncology, orthopedic, cardiology, CNS and neurology, pulmonology, endocrinology, gastroenterology, ophthalmology, nephrology, and others.

The active pharmaceutical ingredient (API) has found its widespread application across cardiology, CNS and neurology, oncology, and endocrinology industrial segments. Cardiology held the highest revenue share in 2018 due to growing occurrences of heart ailments across the globe. The World Health Organization (WHO) in its recent study published that Cardiovascular diseases (CVDs) particularly heart attacks and strokes, have resulted in approximately 17.5 million deaths across the globe. 

Cardiovascular diseases have increasingly been identified as a public health burden and have, therefore, fueled extensive R&D for active pharmaceutical ingredient (API) in the field. Furthermore, oncology is projected to emerge as the fastest-growing market as a result of altering lifestyle leading to rising prevalence of cancer. The active pharmaceutical ingredient (API) is majorly driven by R&D initiatives for the development of novel drugs and biomarkers. The popular APIs utilized for drug processing comprise of Bevacizumab, Rituximab, and Trastuzumab by Roche and Imatinib by Novartis.

Market Insights:

In November 2016, in France, Arrow Generiques SAS, a branch of Aurobindo Pharma Ltd., obtained rights of Calcium products and Calcium Vitamin D3 from Teva Pharmaceutical Industries Ltd.  This will allow Arrow Generiques to continue to expand its branded products’ portfolio and influence its place as a significant player in the drug market. 

Novartis AG is a global health care company that offers and develops solutions to the changing requirements of patients globally. In 2017, Novartis made 16 submissions, received six breakthrough therapy designations, and 16 approvals from the FDA. In addition, companies are accepting the strategy of collaborations and acquisitions with parallel companies in order to strengthen and improve their geographic presence in the global arena.

Key companies operating in the active pharmaceutical ingredient (API) market include AbbVie, Inc.; Teva Pharmaceutical Industries Ltd.; Boehringer Ingelheim International GmbH; Merck & Co., Inc.; Albemarle Corporation; Cipla, Inc.; Mylan N.V.; Bristol-Myers Squibb Company; Dr. Reddy’s Laboratories Ltd; and Aurobindo Pharma.